menu toggle

Company News

Two doctors sitting and looking at an iPad screen together

Lung Cancer
Awareness Month

Sponsored by Jazz Pharmaceuticals

Learn more about a new treatment for lung cancer from Jazz Pharmaceuticals

Industry Spotlights

Now Approved: For ROS1+ NSCLC

November 2025

LUTRATE® DEPOT - AVYXA launches new 505(b)(2) leuprolide acetate

October 2025

Have you seen the new FLAURA2 data?

October 2025

BRUKINSA® (zanubrutinib) Tablets: NOW AVAILABLE

October 2025

Now Available: Docetaxel + Albumin injection (supplied as a kit)

October 2025

See CheckMate-9ER primary analysis and exploratory data in patients who experienced Grade ≥3 TRAEs

October 2025

Starting patients on LORBRENA® (lorlatinib)?

October 2025

NEW ES-SCLC 1st-Line Maintenance Therapy 

October 2025

Learn more: NEW indication for DATROWAY (datopotamab deruxtecan-dlnk)

October 2025

Now approved: Tablet formulation for BRUKINSA®(zanubrutinib)

October 2025

FDA-Approved LIQUID Imatinib for Adult and Pediatric Patients 

October 2025

DOWNLOAD: Dosing guide for LORBRENA® (lorlatinib)

September 2025

What matters to your patients with aOC?

September 2025

Now approved: HERNEXEOS (zongertinib tablets), a once-daily orally administered treatment option

September 2025

Ryzneuta® “Available Now”

September 2025

Explore discontinuation rates for this combination therapy

September 2025

Review 6-year follow-up data in 1L CLL including high-risk patients

September 2025

Tislelizumab-jsgr (TEVIMBRA®) is NOW APPROVED and recommended as a treatment option by NCCN  
 

August 2025

Discover MARGENZA (margetuximab-cmkb)

August 2025

LORBRENA® (lorlatinib) care: Learn what to expect when managing patients

August 2025

There’s ONLY 1 ZOLADEX (goserelin implant)

August 2025

Uncover the latest results for SARCLISA® (isatuximab-irfc)

July 2025

Learn more about the REMS program

July 2025

WATCH: clinical perspectives on data for LORBRENA® (lorlatinib)

July 2025

In RRMM, a new therapeutic target can be your next strategic move

July 2025

Now Approved: For ROS1+ NSCLC

July 2025

Now approved: Tablet formulation for BRUKINSA®(zanubrutinib)

July 2025

J1326: A permanent J-code for VYLOY® (zolbetuximab-clzb) effective July 1

June 2025

A 2L targeted treatment regimen for your eligible patients

June 2025

Explore the new data in unresectable mHCC

June 2025

ZUSDURI™ (mitomycin) for Intravesical Solution (See Prescribing Information)

June 2025

Have you seen this #1 prescribed TKI + IO option in 1L aRCC?

June 2025

Discover the new FDA approval for this I-O therapy

June 2025

Explore a 1L treatment option for ALK+ mNSCLC

June 2025

Now approved for c-Met protein overexpressed 2L+ NSq NSCLC

May 2025

NOW FDA approved: DATROWAY® (datopotamab deruxtecan-dlnk)

May 2025

Now approved for subcutaneous injection

May 2025

300 mg Vial Size Now Available for VYLOY (zolbetuximab-clzb)

May 2025

View safety data at 6-year follow-up from the ELEVATE-TN trial

May 2025

2L DLBCL: See the long-term data

May 2025

NOW APPROVED: A new indication for CABOMETYX® (cabozantinib)

April 2025

2L DLBCL: See the long-term data

April 2025

505(b)(2) Cyclophosphamide Injection

April 2025

Help patients go the distance for long-term PV control

April 2025

What matters to your patients with aOC?

April 2025

NOW ON FORMULARY: FRUZAQLA (fruquintinib) is on Formulary for Your Express Scripts National Formularies Patients

April 2025

2L DLBCL: See the long-term data

April 2025

NEW real-world abiraterone comparison data

March 2025

Save on the only HHI contracted with ION

March 2025

Don’t miss the latest data from CheckMate-9ER

March 2025

Approved indication for certain patients with EGFRm NSCLC

March 2025

Q5146 Q-Code for HERCESSITM (trastuzumab-strf)

February 2025

NOW APPROVED in LS-SCLC

February 2025

Take advantage of this deal

February 2025

Zolbetuximab-clzb (VYLOY) Now Recommended in NCCN Guidelines

February 2025

505(b)(2) Pemetrexed for Injection

January 2025

See the only HHI contracted with ION

January 2025

J0870 permanent J-code for RYTELO (imetelstat)

January 2025

BRAFTOVI® (encorafenib) just landed in a new indication as part of a regimen

January 2025

RE: Phase III data on tolerability in mHSPC

January 2025

Now Approved: A treatment for 3L+ FL

December 2024

Now Approved: A treatment for 3L+ FL

December 2024

Save on the only contracted HHI with ION

December 2024

Save on the only contracted HHI with ION

December 2024

Watch an expert perspective about this 1L aRCC therapy

December 2024

Clinical data for your mHSPC and nmCRPC patients

November 2024

Save with the only contracted HHI for laBCC

November 2024

Guideline Recommendations for Certain Patients With nmCSPC

November 2024

Now FDA approved for advanced gastric/GEJ cancer positive for CLDN18.2

November 2024

How do experts evaluate treatment with CABOMETYX® (cabozantinib) + OPDIVO® (nivolumab)?

October 2024

SCEMBLIX® (asciminib) tablets now approved for a new indication

October 2024

Now Approved: A treatment for 3L+ FL

October 2024

Eribulin Mesylate Injection from Long Grove Pharmaceuticals

October 2024

Learn about the only hedgehog pathway inhibitor (HHI) contracted with ION

October 2024

Discover the Benefits of 2-in-1 for your BRCA+ mCRPC Patients

October 2024

Indication for ENHERTU® (fam-trastuzumab deruxtecan-nxki)

October 2024

505(b)(2) Palonosetron Injection

October 2024

Sponsored: Uncover what only ZOLADEX (goserelin implant) can offer

October 2024

Explore safety data from a 6-year follow-up analysis in 1L CLL

October 2024

Data you'll want to see in 3 indications

September 2024

Sponsored Message: Available for earlier lines—CAR-T cell therapy for RRMM

September 2024

505(b)(2) Cyclophosphamide Injection

August 2024

Discover a versatile treatment option in RRMM

August 2024

Discover potential savings with ION

August 2024

Sponsored: ZOLADEX (goserelin implant) information for AON

August 2024

Sponsored: ZOLADEX (goserelin implant) information for Athena Oncology

August 2024

View a TKI combo Rx option and clinical evidence

August 2024

Dosing options for a RRMM treatment

August 2024

Examine real-world evidence insights on prostate-specific antigen (PSA) in patients with metastatic castration-sensitive prostate cancer (mCSPC)

August 2024

Media mentions

Media Mention

Addressing Access and Affordability Issues With Collaboration at Asembia 2024


May 6, 2024

Learn more

Media Mention

Understanding State Regulations and Advocating for Medically Integrated Dispensing


May 3, 2024

Learn more

Media Mention

Biosimilar Legislation Making Moves in the Right Direction


May 2, 2024

Learn more